This Phase II safety and efficacy trial consisted of three Stages : Stage A and B studies were an expansion of Phase I involving @ and @ subjects respectively , and Stage C was then conducted in two parts ( high dose and low dose ) , each enrolling @ participants : @ borderline lepromatous/lepromatous ( BL/LL ) leprosy patients , @ borderline tuberculoid/tuberculoid ( BT/TT ) leprosy patients , @ household contacts of leprosy patients ( HC ) , and @ tuberculosis ( TB ) patients .